Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene-edited Allogenic CD19 CAR-γδT Cells in r/r B-cell NHL
NCT05554939Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QH103E in non-Hodgkin lymphoma (NHL), sponsored by Chinese PLA General Hospital. Primary endpoints: Incidence of Adverse Events at 12 months, Incidence of Dose-Limiting Toxicities at 28 days and 3 more. Started Dec 2022; status: recruiting.
02
Drugs
QH103E
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05554939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554939.